Market Insights Reports

Cell Free System Overview The global cell free expression market is estimated to be USD 275 million in 2023 and is anticipated to grow at a CAGR of 7.5% till 2035. In recent years, cell free systems / cell free expression systems have emerged as a promising alternative for the conventional cell based biomanufacturing process. It is a well-known fact that traditional biomanufacturing is a complex process that requires living cells and specific conditions in order to maintain pro

...read more

Bacterial infections are known to be one of the leading causes of deaths, worldwide. In fact, infections caused by bacteria are responsible for every one out of eight deaths, globally. This can be attributed to the fact that majority of the pathogenic bacteria have developed resistance against the commonly prescribed therapies. In addition, as per the Centers for Disease Control and Prevention (CDC), the annual healthcare cost associated with treatment of infections caused by six multi-drug resi

...read more

The research and development behind a new drug is reported to require, on an average, an investment of nearly USD 1 billion. At present, over 90% of the drug candidates fail across different stages of clinical trials, leading to significant financial losses for developers. In recent years, with the introduction of industry 4.0 technologies, such as augmented reality, big data, internet of things (IoT) and virtual reality, the digital twins technology has emerged as a promising approach to mitiga

...read more

Animal cell cultures represent an integral part of the drug discovery and development process.  The conventional 2 dimensional (2D) cell culturing format is still extensively used in early stage research and is instrumental in establishing initial proof-of-concept and validating mechanisms of action of pharmacological leads. However, over time, it has been demonstrated that such cultures are unable to accurately mimic the natural (in vivo) microenvironment. Moreover, cells cultured in monol

...read more

With close to 80 monoclonal antibodies approved till date, and over 550 molecules in the clinical pipeline, antibody based pharmacological interventions have become an important part of the biopharmaceutical industry.  In fact, they are presently estimated to constitute the largest class of biologics in the industry. Examples of recently approved monoclonal antibody products include (in reverse chronological order) Adakveo® (November 2019), Beovu® (October 2019), SKYRIZI™ (Apr

...read more
  • why-choose

    We are your partners with no equity

  • budget

    We fit in your budget

  • love

    We love what we do

  • treat

    Chance to prove ourselves

  • quality

    Best in class quality of work

  • trusted

    Most trusted consulting partner in the industry